CION Ameerpet
CION 1-year survival*
80.0%
Medically reviewed by Dr. Naresh Gundu, Medical Oncologist · Last reviewed June 2026
For recurrent or metastatic oral cancer, immunotherapy has changed what is possible. Drugs like pembrolizumab and nivolumab work by releasing the brakes on your own immune system so it can recognise and attack cancer cells. At CION Cancer Clinics, our medical oncology team delivers these checkpoint inhibitors in line with the KEYNOTE-048 trial and NCCN guidelines — starting with PD-L1 CPS testing to confirm whether immunotherapy is right for you.
Immunotherapy is a type of cancer treatment that uses your own immune system to fight cancer. Oral cancer cells can hide from the immune system by switching on a protein called PD-L1, which acts as a brake on the immune cells (T-cells) that would normally attack them. Immunotherapy drugs called checkpoint inhibitors block this brake — allowing the immune system to recognise and destroy the cancer.
For oral cancer, immunotherapy is not a first-choice treatment for early-stage disease — surgery, radiation, and chemoradiation remain the foundation there. Instead, immunotherapy has its most important role in recurrent or metastatic oral cancer — cancer that has come back after treatment or spread to other parts of the body. In this setting, the KEYNOTE-048 trial established immunotherapy as the new first-line standard of care.
The most commonly used immunotherapy drugs for oral and head and neck cancer target the PD-1 / PD-L1 pathway:
Immunotherapy is not suitable for every patient with oral cancer. Whether it is right for you depends on the stage, whether the cancer has recurred or spread, your PD-L1 CPS score, and your overall health. A medical oncologist and tumour board review is the only way to know — we walk this decision through with you, step by step.
The KEYNOTE-048 trial showed that patients with PD-L1 CPS ≥20 treated with pembrolizumab alone had a median overall survival of 23.4 months — more than double the 10.7 months achieved with the previous cetuximab-based EXTREME regimen. This is why PD-L1 CPS testing at diagnosis is now essential for every patient with recurrent or metastatic oral cancer. (Source: Burtness B, et al. KEYNOTE-048, The Lancet 2019; NCCN Head and Neck Cancers Guidelines.)
Immunotherapy works very differently from chemotherapy. Rather than directly poisoning fast-dividing cells, it re-trains your immune system to do the work. Understanding the mechanism helps you understand why the side-effect pattern, response timing, and monitoring are also different. Tap any point to expand.
Your body's T-cells constantly patrol for abnormal cells, including cancer. Oral squamous cell carcinoma, however, often carries a high number of genetic mutations — particularly tobacco-related cancers — which makes it visible to the immune system in principle. The problem is not that the immune system cannot see the cancer; it is that the cancer has learned to switch the immune response off. Immunotherapy is built on the insight that the immune system already has the machinery to destroy the tumour — it just needs the brakes released.
Healthy cells use a checkpoint called PD-L1 to tell passing T-cells "I am normal — do not attack." Many oral cancers hijack this signal, coating themselves in PD-L1 so that when a T-cell's PD-1 receptor touches it, the T-cell stands down. This is the molecular trick that lets the tumour grow unchecked despite an otherwise capable immune system. The amount of PD-L1 a tumour displays — measured as the Combined Positive Score, or CPS — directly predicts how likely immunotherapy is to work.
Pembrolizumab and nivolumab are monoclonal antibodies that physically block the PD-1 receptor on T-cells. With PD-1 blocked, the cancer's PD-L1 signal can no longer switch the T-cell off — the brake is released and the immune system is free to attack the tumour again. Because the drug acts on the immune system rather than on the cancer cell directly, the effect can continue working long after each infusion, and in some patients responses are unusually durable compared with chemotherapy.
Unlike chemotherapy, which can shrink tumours within days, immunotherapy works at the pace of the immune system. It can take several weeks to a few months for the immune response to build and for scans to show benefit. Occasionally a tumour appears slightly larger on an early scan before it shrinks — a phenomenon called pseudo-progression caused by immune cells flooding into the tumour. This is why your oncologist interprets early scans carefully and does not stop effective treatment prematurely.
Because immunotherapy activates the immune system, its side effects are immune-related rather than the hair loss and severe nausea typical of chemotherapy. Most patients tolerate it well, but the activated immune system can occasionally attack healthy organs — causing inflammation of the skin, gut (colitis), thyroid, lungs (pneumonitis), or liver. Most of these are manageable when caught early, which is why regular monitoring and prompt reporting of new symptoms are an essential part of safe immunotherapy.
The Combined Positive Score (CPS) counts PD-L1-positive tumour and immune cells relative to total tumour cells. The KEYNOTE-048 trial showed that the higher the CPS, the greater the benefit from pembrolizumab: patients with CPS ≥20 may do well on pembrolizumab alone, while those with CPS ≥1 generally benefit more from pembrolizumab combined with chemotherapy. CPS testing on biopsy tissue is therefore the first step at CION before any recommendation — it personalises the regimen rather than applying a one-size-fits-all approach.
Immunotherapy is not the right first step for every oral cancer. It is most valuable in specific clinical situations, which your medical oncologist will confirm after reviewing your pathology, imaging, and PD-L1 status:
Immunotherapy is generally avoided or used cautiously in patients with active autoimmune disease, those on high-dose immunosuppression, or after solid-organ transplant — because releasing the immune brake can worsen these conditions. Your tumour board weighs every one of these factors before recommending treatment.
India accounts for approximately one-third of the world's oral cancer cases, and many patients present at an advanced stage where systemic therapy matters most. For these patients, immunotherapy has shifted survival expectations — yet PD-L1 CPS testing, which decides who benefits, is still not routinely offered everywhere. CION performs PD-L1 CPS testing on biopsy tissue for all recurrent or metastatic oral cancer. (Source: ICMR National Cancer Registry Programme; NCCN Head and Neck Cancers Guidelines.)
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Same-week appointments and a dedicated second-opinion pathway across 35+ centres in Telangana & AP.
Immunotherapy is a carefully sequenced process, not a single decision. CION's pathway is aligned with NCCN and ESMO standards and is reviewed by a multidisciplinary tumour board at every step.
We confirm the histology (oral squamous cell carcinoma) and establish whether the disease is recurrent or metastatic using imaging — CT, MRI, or PET-CT. Immunotherapy is considered only when local treatments such as surgery or radiation are no longer the best option.
PD-L1 expression is measured on biopsy or surgical tissue and reported as a Combined Positive Score (CPS). This score determines immunotherapy eligibility and whether pembrolizumab is best given alone (CPS ≥20) or with chemotherapy (CPS ≥1).
Medical, surgical, and radiation oncologists review your case together and agree the regimen — pembrolizumab alone, pembrolizumab plus platinum and 5-FU, or nivolumab after platinum therapy. We explain the plan, the expected benefit, and the costs before anything begins.
Checkpoint inhibitors are given as an intravenous infusion in a day-care setting, typically every 3 or 6 weeks. Blood tests and clinical reviews before each cycle watch for immune-related side effects so they can be managed early.
Scans are repeated after a few cycles to assess response, interpreted carefully to account for the slower, sometimes delayed response pattern of immunotherapy. Treatment continues as long as it is working and well tolerated.
CION's medical oncology team delivers immunotherapy in line with current NCCN and ESMO guidelines. The exact drug and regimen depend on your PD-L1 CPS score and whether you have had previous platinum-based chemotherapy. Tap any option to expand.
For recurrent or metastatic oral cancer with a high PD-L1 score (CPS ≥20), the KEYNOTE-048 trial supports pembrolizumab given on its own as first-line treatment. In this group, pembrolizumab monotherapy improved overall survival compared with the older cetuximab-based EXTREME regimen, and with fewer side effects than adding chemotherapy.
For patients with PD-L1 CPS ≥1 — or when more rapid disease control is needed — pembrolizumab is combined with platinum chemotherapy and 5-fluorouracil. KEYNOTE-048 showed this combination improved overall survival versus the EXTREME regimen across the CPS ≥1 population. The chemotherapy adds early tumour control while the immunotherapy provides the durable benefit.
For oral or head and neck cancer that has progressed on or within 6 months of platinum-based chemotherapy, nivolumab is an established second-line option. The CheckMate-141 trial demonstrated improved overall survival versus standard single-agent therapy in this setting, making it a valuable choice when first-line treatment has stopped working.
Immunotherapy is not the answer for everyone. For tumours with PD-L1 CPS <1, or for patients with active autoimmune disease or other contraindications to checkpoint inhibitors, the cetuximab-based EXTREME regimen or platinum chemotherapy may be the better choice. CION's tumour board evaluates all of these options together so that the recommendation fits your biology and your overall health — not just the newest available drug.
Immunotherapy offers real advantages for the right patients — but it works differently from chemotherapy, and knowing what to expect helps you make an informed decision with your oncologist.
When immunotherapy works, the benefit can be unusually long-lasting compared with chemotherapy — in some patients responses continue well after treatment cycles, because the immune system keeps working.
Most patients avoid the hair loss and severe nausea of chemotherapy. Immunotherapy is generally well tolerated, though immune-related side effects need careful monitoring.
Immunotherapy works at the pace of the immune system. It may take weeks to months to see benefit on scans — your oncologist interprets early imaging carefully to avoid stopping effective treatment too soon.
An activated immune system can occasionally inflame the skin, gut, thyroid, lungs, or liver. Most are manageable when reported early — which is why we monitor blood tests and symptoms before every cycle.
Treatment is given intravenously in a day-care setting, usually every 3 or 6 weeks — no overnight hospital stay is needed for the infusion itself in most cases.
PD-L1 CPS testing means treatment is matched to your tumour biology — not a one-size-fits-all approach. The score guides whether immunotherapy is used alone or combined with chemotherapy.
The cost of immunotherapy for oral cancer in Hyderabad depends on the drug, the dose (which is weight-based), the number of cycles, and whether chemotherapy is combined. The reference ranges below are indicative; a personalised estimate is provided after your medical oncology consultation at CION.
| Treatment | Approx. Cost (INR) | Notes |
|---|---|---|
| PD-L1 CPS Testing (one-time) | ₹8,000 – ₹20,000 | Immunohistochemistry on biopsy tissue; decides eligibility |
| Pembrolizumab (per cycle) | ₹1,00,000 – ₹2,50,000 | Dose and brand dependent; given every 3–6 weeks |
| Nivolumab (per cycle) | ₹80,000 – ₹2,00,000 | Weight-based dosing; second-line after platinum |
| Pembrolizumab + Chemotherapy (per cycle) | ₹1,50,000 – ₹3,00,000 | Adds platinum + 5-FU to immunotherapy |
Costs are indicative and vary by drug, dose, and number of cycles. Insurance coverage for immunotherapy varies by insurer. A personalised cost estimate is provided following your initial oncology consultation at CION.
Both immunotherapy and chemotherapy are systemic treatments, but they work in fundamentally different ways. This comparison is general — your oncologist will explain which is right for your specific situation.
| Feature | Immunotherapy (PD-1 inhibitors) | Chemotherapy |
|---|---|---|
| How it works | Activates your own immune system to attack cancer | Directly kills fast-dividing cells, including cancer |
| Speed of response | Slower — weeks to months | Often faster — within days to weeks |
| Duration of benefit | Can be durable, sometimes long after treatment | Usually continues only while on treatment |
| Typical side effects | Immune-related — skin, gut, thyroid, lung, liver inflammation | Hair loss, nausea, low blood counts, fatigue |
| Biomarker guidance | PD-L1 CPS predicts likely benefit | Not biomarker-selected for oral cancer |
| Main role in oral cancer | Recurrent / metastatic disease | Concurrent with radiation, or palliative systemic therapy |
*1-year survival rates for oral cancer patients at CION Cancer Clinics vs the national average reported by ICMR / National Cancer Registry Programme (NCRP). Higher CION outcomes reflect specialist tumour-board care, NCCN-aligned protocols including immunotherapy, and integrated supportive-care pathways.
Because immunotherapy activates the immune system, side effects are immune-related and can affect almost any organ. Most are mild and manageable when reported early. At CION, structured monitoring is built into every cycle:
Report any new or unusual symptom to your CION team straight away — do not wait for your next appointment. Most immune-related side effects are fully manageable when treated early, and many patients continue immunotherapy safely afterwards.
Biomarker-guided immunotherapy, KEYNOTE-048 protocols, and tumour-board review for every patient — across 35+ centres in Telangana & AP.
17 Super-Specialist Oncologists
35+ Centres Across Telangana & AP
5-Star NABH Accredited
KEYNOTE-048 & NCCN Protocols
PD-L1 CPS Biomarker Testing
Multidisciplinary tumour board
Structured side-effect monitoring
Full integrative support
Dedicated Second Opinion service
EMI Facility
4.8 / 5 Google rating
15,000+ patients treated
CION Cancer Clinics is India's fastest-growing cancer care network, with 35+ centres across Telangana and Andhra Pradesh. Dedicated exclusively to oncology, CION delivers NABH-accredited, NCCN and ESMO protocol-driven cancer care — including biomarker-guided immunotherapy — bringing world-class treatment closer to patients across the region.
Disclaimer: This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Immunotherapy decisions depend on individual factors including stage, PD-L1 status, and overall health, and must be made with a qualified oncologist. The information on this page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines.
Immunotherapy is given on the immune system's timeline, not chemotherapy's — which is why a tumour can occasionally look slightly larger on an early scan before it shrinks. This is called pseudo-progression, caused by immune cells flooding into the tumour. An experienced medical oncologist interprets these early scans carefully so that effective treatment is not stopped too soon. (Source: NCCN Head and Neck Cancers Guidelines; iRECIST response criteria.)
From early-stage oral lesions to advanced systemic therapy — the people behind our 4.8 / 5 Google rating.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Immunotherapy for oral cancer is a treatment that uses your own immune system to fight the cancer. Oral cancers can hide from the immune system by displaying a protein called PD-L1, which switches off the immune cells (T-cells) that would otherwise attack them. Immunotherapy drugs called checkpoint inhibitors — mainly pembrolizumab (Keytruda) and nivolumab (Opdivo) — block this signal and allow the immune system to recognise and destroy the cancer again. It is used mainly for recurrent or metastatic oral squamous cell carcinoma, where the KEYNOTE-048 trial established it as the first-line standard of care.
Yes — for the right patients. The KEYNOTE-048 trial showed that pembrolizumab improved overall survival in recurrent or metastatic head and neck cancer, including oral cavity cancer, compared with the older cetuximab-based EXTREME regimen. In patients with a high PD-L1 score (CPS ≥20), pembrolizumab alone roughly doubled median overall survival in the trial. The key is patient selection — immunotherapy is most effective in PD-L1-positive recurrent or metastatic disease, which is why PD-L1 CPS testing is done before treatment. It is not the first-choice treatment for early-stage oral cancer, where surgery and radiation remain the foundation.
Immunotherapy is mainly considered for patients with recurrent oral cancer (returned after earlier treatment) or metastatic oral cancer (spread to other parts of the body) when further surgery or radiation is not the best option. Candidates usually have PD-L1-positive tumours (CPS ≥1), confirmed on biopsy tissue, and are well enough to tolerate treatment and attend monitoring. Nivolumab is an option for disease that has progressed after platinum-based chemotherapy. Immunotherapy is generally avoided in patients with active autoimmune disease or those on strong immunosuppression. Your medical oncologist and tumour board confirm suitability after reviewing your pathology, scans, and PD-L1 status.
PD-L1 CPS testing measures how much PD-L1 protein your tumour displays, reported as a Combined Positive Score (CPS) on biopsy or surgical tissue. The score predicts how likely immunotherapy is to work and guides the regimen. In the KEYNOTE-048 trial, patients with CPS ≥20 benefited from pembrolizumab alone, while those with CPS ≥1 generally benefited more from pembrolizumab combined with chemotherapy. Because the score directly shapes the treatment plan, CION performs PD-L1 CPS testing as the first step for every patient with recurrent or metastatic oral cancer before recommending immunotherapy.
Because immunotherapy activates the immune system, its side effects are immune-related rather than the hair loss and severe nausea typical of chemotherapy. The most common are skin rash and fatigue. Less commonly, the activated immune system can inflame the gut (causing diarrhoea or colitis), the thyroid and other hormone glands, the lungs (pneumonitis), or the liver. Most of these are mild and fully manageable when reported early, which is why CION checks blood tests and reviews symptoms before every cycle. You should report any new or unusual symptom straight away rather than waiting for your next appointment.
Immunotherapy drugs like pembrolizumab and nivolumab are given as an intravenous (IV) infusion in a day-care setting — usually no overnight hospital stay is needed for the infusion itself. Pembrolizumab is typically given every 3 or 6 weeks, depending on the dose schedule. Before each cycle, you have blood tests and a clinical review to check for side effects. Treatment usually continues as long as it is working and well tolerated. Scans are repeated after a few cycles to assess response, interpreted carefully because immunotherapy can take longer than chemotherapy to show benefit.
The cost depends on the drug, the dose (which is based on body weight), the number of cycles, and whether chemotherapy is combined. As an indicative guide in Hyderabad: PD-L1 CPS testing costs around ₹8,000 to ₹20,000 as a one-time test; pembrolizumab costs roughly ₹1,00,000 to ₹2,50,000 per cycle; and nivolumab roughly ₹80,000 to ₹2,00,000 per cycle. Pembrolizumab combined with chemotherapy is higher. Insurance coverage for immunotherapy varies by insurer and policy. CION provides a personalised cost estimate after your consultation, offers EMI options for all patients, and helps explore patient access programmes where available.
Neither is universally better — they work differently and suit different situations. Chemotherapy directly kills fast-dividing cells and often works faster, but its benefit usually lasts only while you are on treatment, and it causes hair loss, nausea, and low blood counts. Immunotherapy activates your own immune system; it works more slowly but can produce durable responses, and is often better tolerated. For recurrent or metastatic oral cancer with PD-L1 CPS ≥1, the KEYNOTE-048 trial supports immunotherapy (with or without chemotherapy) as first-line treatment. The right choice depends on your PD-L1 status, disease burden, and overall health — decided by your tumour board.
Immunotherapy works at the pace of the immune system, so it is generally slower than chemotherapy. It can take several weeks to a few months for the immune response to build and for scans to show clear benefit. Occasionally a tumour can appear slightly larger on an early scan before it shrinks — a phenomenon called pseudo-progression, caused by immune cells flooding into the tumour. For this reason, your oncologist interprets early imaging carefully and uses immunotherapy-specific response criteria so that effective treatment is not stopped prematurely. When immunotherapy does work, the benefit can be unusually long-lasting.
Absolutely — and for immunotherapy decisions it is strongly advisable, because the choice between immunotherapy, chemotherapy, and the cetuximab-based regimen depends on details like your PD-L1 CPS score, prior treatment, and overall health. CION offers a dedicated Second Opinion service where our multidisciplinary tumour board reviews your biopsy, PD-L1 report, imaging, and any existing treatment recommendation. This is especially valuable when you want to confirm that PD-L1 testing has been done, understand whether immunotherapy alone or with chemotherapy is right for you, or weigh immunotherapy against other systemic options. You can send your reports for review without any commitment to start treatment at CION.